Anyone else adding to VEEV?

=== SUMMARY === - Author is bullish on VEEV (Veeva Systems), citing zero debt, a large cash pile, a $2B buyback, S&P 500 inclusion, a PE ratio at one-third of its historical high, and a monopoly in highly regulated healthcare/drug trial software. - Thesis: VEEV is oversold due to temporary concerns; the upcoming May 27 earnings will confirm strength, aided by the Salesforce “divorce” and successful Vault platform migrations. - Quality assessment: Moderately well-researched DD with specific financial metrics, catalyst dates, and industry moat reasoning, though lacks detailed competitor analysis or downside risks. === SENTIMENT === BULLISH === TRADE IDEAS === VEEV - LONG | confidence: 0.80 | sentiment: +0.70 Speaker: u/No-Calligrapher-1649 Thesis: 1. THE FACT: VEEV has no debt, $2B buyback, S&P 500 inclusion, and a PE at ~1/3 of historical peak; average analyst target implies 60% upside. 2. THE BRIDGE: These fundamentals, combined with a regulatory moat and upcoming earnings catalyst, suggest the market is mispricing the stock relative to intrinsic value. 3. THE VERDICT: Long VEEV as a value play with a near-term catalyst (May 27 earnings) and strong operational tailwinds from the Salesforce transition. 4. RISKS: Earnings miss on May 27; longer-than-expected migration costs; AI disruption or new entrants in clinical trial software; broader tech sell-off. Timeframe: short-term (earnings catalyst) / medium-term (value realization) Key Points: - Zero debt + $2B buyback = strong balance sheet - S&P 500 inclusion adds institutional floor - PE at ~1/3 historical max suggests undervaluation - Regulatory moat protects from AI disruption - May 27 earnings is key catalyst